American Association for Cancer Research
15357163mct121173-sup-tab1.xls (30 kB)

Supplementary Table 1 from DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody–Drug Conjugate, Is a Potential Treatment for Non-Hodgkin Lymphoma

Download (30 kB)
posted on 2023-04-03, 14:09 authored by Dongwei Li, Kirsten Achilles Poon, Shang-Fan Yu, Randall Dere, MaryAnn Go, Jeffrey Lau, Bing Zheng, Kristi Elkins, Dimitry Danilenko, Katherine R. Kozak, Pamela Chan, Josefa Chuh, Xiaoyan Shi, Denise Nazzal, Franklin Fuh, Jacqueline McBride, Vanitha Ramakrishnan, Ruth de Tute, Andy Rawstron, Andrew S. Jack, Rong Deng, Yu-Waye Chu, David Dornan, Marna Williams, William Ho, Allen Ebens, Saileta Prabhu, Andrew G. Polson

XLSX file - 30K, IC50 concentrations and CD22 expression levels for cell lines.



Antibody–drug conjugates (ADC), potent cytotoxic drugs linked to antibodies via chemical linkers, allow specific targeting of drugs to neoplastic cells. We have used this technology to develop the ADC DCDT2980S that targets CD22, an antigen with expression limited to B cells and the vast majority of non-Hodgkin lymphomas (NHL). DCDT2980S consists of a humanized anti-CD22 monoclonal IgG1 antibody with a potent microtubule-disrupting agent, monomethyl auristatin E (MMAE), linked to the reduced cysteines of the antibody via a protease cleavable linker, maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl (MC-vc-PAB). We describe the efficacy, safety, and pharmacokinetics of DCDT2980S in animal models to assess its potential as a therapeutic for the treatment of B-cell malignancies. We did not find a strong correlation between in vitro or in vivo efficacy and CD22 surface expression, nor a correlation of sensitivity to free drug and in vitro potency. We show that DCDT2980S was capable of inducing complete tumor regression in xenograft mouse models of NHL and can be more effective than rituximab plus combination chemotherapy at drug exposures that were well tolerated in cynomolgus monkeys. These results suggest that DCDT2980S has an efficacy, safety, and pharmacokinetics profile that support potential treatment of NHL. Mol Cancer Ther; 12(7); 1255–65. ©2013 AACR.

Usage metrics

    Molecular Cancer Therapeutics



    Ref. manager